Investing in Japan
Latest UpdatesTLC, a Taiwan-based biopharmaceutical company, launches its business in Japan
Oct 01, 2015
In January 2015, Taiwan-based biopharmaceutical company, TLC (Taiwan Liposome Company, Ltd.), established its Japanese subsidiary in Tokyo. This subsidiary will be dedicated towards obtaining approval for its super-generic and new prescription drugs, and developing new partnerships, as well as strengthening relationships with its existing Japanese partners.
TLC specializes in developing improved treatments for cancer, retinal disorders and infectious diseases. Besides Tokyo, TLC has established overseas subsidiaries in South San Francisco (US), Leiden (EU), Melbourne (Australia) and Shanghai (China). As a long term goal, TLC is looking to engage in research and development collaborations with local Japanese partners, as well as become a MAH (Market Authorization Holder) for its pharmaceutical products in Japan.
In order to support the establishment of a high value-added base in Japan, JETRO provided services such as the introduction of Japanese medical and research organizations, and business matching. Prior to its entry into the Japanese market, JETRO’s Invest Japan Business Support Center (IBSC) provided a range of services including temporary office space, industry information, as well as consultation with experts regarding visa, labor law and pharmaceutical affairs.